Clevidipine (the Medicines Company)
- PMID: 12431021
Clevidipine (the Medicines Company)
Abstract
The Medicines Company (under license from AstraZeneca) is developing clevidipine, a short-acting dihydropyridine calcium antagonist, for the potential treatment of peri-operative hypertension. By 1997, the compound was undergoing phase II clinical evaluation by the original developer, AstraZeneca. By March 2002, The Medicines Company was conducting phase III clinical trials.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical